Psychology Research and Behavior Management (Oct 2022)

Serum CC Chemokines as Potential Biomarkers for the Diagnosis of Major Depressive Disorder

  • Gao W,
  • Xu Y,
  • Liang J,
  • Sun Y,
  • Zhang Y,
  • Shan F,
  • Ge J,
  • Xia Q

Journal volume & issue
Vol. Volume 15
pp. 2971 – 2978

Abstract

Read online

Wenfan Gao,1– 4,* Yayun Xu,5– 7,* Jun Liang,1– 4 Yanhong Sun,1– 4 Yuanyuan Zhang,1– 4 Feng Shan,1– 4 Jinfang Ge,6– 8 Qingrong Xia1– 4 1Affiliated Psychological Hospital of Anhui Medical University, Hefei, People’s Republic of China; 2Department of Pharmacy, Hefei Fourth People’s Hospital, Hefei, People’s Republic of China; 3Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, People’s Republic of China; 4Anhui Clinical Research Center for Mental Disorders, Hefei, People’s Republic of China; 5Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, People’s Republic of China; 6Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, People’s Republic of China; 7The Key Laboratory of Anti-Inflammatory and Immune Medicines, Ministry of Education, Hefei, People’s Republic of China; 8School of Pharmacy, Anhui Medical University, Hefei, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jinfang Ge, School of Pharmacy, Anhui Medical University, 81 Meishan Road, Hefei, 230000, People’s Republic of China, Email [email protected] Qingrong Xia, Department of Science and Education, Hefei Fourth People’s Hospital, Affiliated Psychological Hospital of Anhui Medical University, Anhui Mental Health Center, 316 Huangshan Road, Hefei, 230000, People’s Republic of China, Email [email protected]: Evidence indicates a potential role of chemokines in depression-like behavior and depression-related pathophysiological processes. In the present study, we examined the serum levels of multiple chemokines, focusing on CC chemokines, in patients with major depressive disorder (MDD), with the aim to discover and identify serum chemokines-based biomarkers for MDD diagnosis.Methods: Participants included 24 patients with MDD and 24 healthy controls. The 24-item Hamilton Depression Rating Scale (HAMD-24) was administered to assess the disease severity of patients with MDD. A total of 9 serum CC chemokines including MCP-1 (CCL-2), MIP-1α (CCL-3), MIP-1β (CCL-4), eotaxin-1 (CCL-11), MCP-4 (CCL-13), TARC (CCL-17), MIP-3α (CCL-20), MDC (CCL-22), and Eotaxin-3 (CCL-26) were measured using electrochemiluminescence immunoassays. The levels of serum CC chemokines between MDD group and control group were compared, and diagnostic values of different CC chemokines were evaluated using the receiver operating characteristic (ROC) curve method for discriminating MDD patients from healthy controls. Correlations between the levels of serum CC chemokines and depression severity (HAMD-24 scores) were evaluated using Pearson’s correlation test.Results: Patients with MDD had higher levels of serum MIP-1α and MIP-1β and lower levels of serum MCP-1, MCP-4, TARC, MDC, and Eotaxin-3 compared to controls (all P 0.7 in discriminating patients with MDD from healthy controls. Furthermore, no significant relationship was found between the levels of serum CC chemokines and HAMD-24 scores in MDD group.Conclusion: These results suggested that circulating CC chemokines may hold promise in the discovery of biomarkers for diagnosing MDD.Keywords: chemokines, biomarker, diagnosis, serum, major depressive disorder

Keywords